Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.40 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.39 |
| ▸ | ELANE | P08246 | 5/20 | 0.38 |
| ▸ | CMA1 | P23946 | 2/20 | 0.37 |
| ▸ | CTRC | Q99895 | 2/20 | 0.37 |
| ▸ | F3 | P13726 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 5/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31558568 | 0.87 | NTRK1 (0.45) | CASP1NTRK1NTRK3ELANECMA1 | |
| SCHEMBL30765732 | 0.86 | NTRK1 (0.40) | CASP1NTRK1NTRK3ELANECMA1 | |
| SCHEMBL30765697 | 0.84 | F2 (0.43) | CASP1NTRK1NTRK3ELANECMA1 | |
| SCHEMBL30765851 | 0.84 | NTRK1 (0.40) | CASP1NTRK1NTRK3ELANECMA1 | |
| SCHEMBL30765974 | 0.84 | CASP1 (0.44) | CASP1NTRK1NTRK3ELANECMA1 | |
| SCHEMBL30765954 | 0.83 | HDAC1 (0.40) | CASP1NTRK1NTRK3ELANECMA1 | |
| SCHEMBL30766050 | 0.83 | ELANE (0.41) | CASP1NTRK1NTRK3ELANECMA1 | |
| SCHEMBL30765624 | 0.83 | CASP1 (0.42) | CASP1NTRK1NTRK3ELANECMA1 | |
| SCHEMBL30766049 | 0.83 | NTRK1 (0.43) | CASP1NTRK1NTRK3ELANECMA1 | |
| Hydrochloric Acid SCHEMBL30765434 | 0.82 | NTRK1 (0.43) | CASP1NTRK1NTRK3ELANECMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4568666-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Alexion Pharmaceuticals, Inc. (US) | 2025-06-18 | — | — | EP | disclosed |
| CN-119768164-A | Pharmaceutical compounds for treating complement-mediated disorders | 阿雷克森制药公司 | 2025-04-04 | — | — | CN | disclosed |
| WO-2024035686-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2024-02-15 | — | — | WO | disclosed |